Kairos Pharma, LTD. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Bhowmick Neil | Chief Scientific Officer | Award / Grant | 171,756 | — | — | 1,311,739 | Oct 8, 2025 |
| Bae Hyun W. | — | Award / Grant | 10,000 | — | — | 54,286 | Oct 8, 2025 |
| Murali Ramachandran | VP of Research and Development | Award / Grant | 152,672 | — | — | 299,529 | Oct 8, 2025 |
| Singhvi Rahul | — | Award / Grant | 19,084 | — | — | 49,204 | Oct 8, 2025 |
| Samuelson Doug | Chief Financial Officer | Award / Grant | 152,672 | — | — | 293,039 | Oct 8, 2025 |
| Yu John S | CEO and Chairman | Award / Grant | 190,840 | — | — | 230,105 | Oct 8, 2025 |
| Keyoung Hansoo Michael | — | Award / Grant | 19,084 | — | — | 29,084 | Sep 16, 2025 |
| Bhowmick Neil | Chief Scientific Officer | Award / Grant | 14,000 | — | — | 1,139,983 | Jan 1, 2025 |
| Murali Ramachandran | VP of Research and Development | Award / Grant | 14,000 | — | — | 147,057 | Jan 1, 2025 |
| Yu John S | CEO and Chairman | Award / Grant | 14,000 | — | — | 5,355,838 | Jan 1, 2025 |
| Murali Ramachandran | VP of Research and Development | Purchase | 200 | $1.59 | $318 | 133,057 | Nov 25, 2024 |
| Samuelson Doug | Chief Financial Officer | Purchase | 2,500 | $1.50 | $3,750 | 60,796 | Nov 22, 2024 |
| Yu John S | CEO and Chairman | Purchase | 4,000 | $1.44 | $5,760 | 5,341,837 | Nov 20, 2024 |